PECS-2 for Breast Surgery

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 23, 2017

Primary Completion Date

October 22, 2020

Study Completion Date

October 22, 2020

Conditions
Breast Neoplasm FemaleRegional AnesthesiaAnesthesiaRegional Anesthesia MorbidityAnesthesia Morbidity
Interventions
DRUG

Ropivacaine 5 mg/ml, 35 ml

Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.

DRUG

Remifentanil 50 microg/ml

The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.

DRUG

Betamethason 4 mg

Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.

DRUG

Paracetamol 1,5 g

Administered preoperatively to prevent pain postoperatively.

DRUG

Propofol

The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.

DRUG

Arcoxia, 120 mg

Administered preoperatively to prevent pain postoperatively.

DRUG

Ondansetron 4 mg

Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.

DRUG

Morphine

Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.

Trial Locations (1)

83183

Östersund Hospital, Östersund

All Listed Sponsors
lead

Umeå University

OTHER

NCT03117894 - PECS-2 for Breast Surgery | Biotech Hunter | Biotech Hunter